IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Monday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of IRIDEX stock opened at $1.65 on Monday. The stock has a market cap of $27.46 million, a price-to-earnings ratio of -2.46 and a beta of 0.82. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. The stock has a 50 day moving average price of $1.73 and a 200-day moving average price of $1.79. IRIDEX has a one year low of $1.27 and a one year high of $3.65.

IRIDEX (NASDAQ:IRIX) last posted its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The business had revenue of $11.58 million for the quarter. During the same period in the prior year, the firm posted ($0.11) EPS.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.